Quick Answer
CNBX Pharmaceuticals Inc. reported Net Income of -$314.0 thousand for fiscal year 2025.
CNBX Pharmaceuticals Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$314.0K | +54.8% |
| 2024 | -$695.2K | +81.3% |
| 2023 | -$3.71M | +0.3% |
| 2022 | -$3.72M | -16.6% |
| 2021 | -$3.19M | +57.2% |
| 2020 | -$7.47M | -759.1% |
| 2019 | $1.13M | +130.0% |
| 2018 | -$3.78M | -95.3% |
| 2017 | -$1.93M | -529.5% |
| 2016 | -$307.2K | +43.3% |
| 2015 | -$541.4K | -100.5% |
| 2014 | -$270.0K | -378.7% |
| 2013 | -$56.4K | -3314.1% |
| 2012 | -$1.7K | +98.5% |
| 2011 | -$107.3K | +6.7% |
| 2010 | -$115.0K | -0.1% |
| 2009 | -$114.9K | -318.5% |
| 2008 | -$27.5K | -18.3% |
| 2007 | -$23.2K | -15.9% |
| 2006 | -$20.0K | -1012.3% |
| 2005 | -$1.8K | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| November 30, 2025 | -$113.7K | -231.0% | -90.4% |
| May 31, 2025 | -$59.7K | +54.3% | +14.4% |
| February 28, 2025 | -$69.8K | +78.6% | -103.2% |
| November 30, 2024 | -$34.4K | +80.8% | +73.7% |
| May 31, 2024 | -$130.6K | +15.6% | +59.9% |
| February 29, 2024 | -$325.5K | +87.6% | -82.3% |
| November 30, 2023 | -$178.5K | +50.1% | -15.4% |
| May 31, 2023 | -$154.7K | +77.3% | +94.1% |
- CNBX Pharmaceuticals Inc. showed an increase of +54.8% in Net Income compared to the prior fiscal year.
- Over the 2005–2025 period, CNBX Pharmaceuticals Inc.’s net income has declined by 17343.1% (from -$1.8 thousand to -$314.0 thousand).
- The most recent figure is from CNBX Pharmaceuticals Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on December 1, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: